Tech Company Financing Transactions
Klotho Therapeutics Funding Round
On 11/4/2017, Klotho Therapeutics raised $10 million in Series A funding from Thynk Capital and private investors.
Transaction Overview
Company Name
Announced On
11/4/2017
Transaction Type
Venture Equity
Amount
$10,000,000
Round
Series A
Investors
Thynk Capital (Lead Investor)
Proceeds Purpose
Proceeds of the financing will fund KTI's manufacturing scale-up, first in-human studies and Investigational New Drug (IND) application with the FDA.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
San Diego, CA 92130
USA
San Diego, CA 92130
USA
Phone
Undisclosed
Website
Email Address
Overview
KLOTHO Therapeutics (KTI) is a biotechnology company developing a patent-pending Klotho protein that has great potential to redefine society's experience with aging. KTI has worldwide patents pending on versions of modified, recombinant Klotho that can be manufactured using standard cell culture technology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
James Plante
VP - Bus. Development
William Ramage
VP - Operations
Dinesh Raturi
Browse more venture capital transactions:
Prev: 11/4/2017: PathAI venture capital transaction
Next: 11/4/2017: Brat venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on all VC transactions involving tech companies. VC transactions reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs